Clinical Outcomes of Patients with EGFR T790M+NSCLC on Osimertinib

被引：0
|
作者：
Tan, W. L. [1 ]
Hennedige, T. P. [2 ]
Ng, Q. S. [3 ]
Tan, S. H. [4 ]
Tran, N. T. A. [5 ]
Chua, B. J. G. [6 ]
Toh, C. K. [3 ]
Tan, E. H. [3 ]
Tan, D. [3 ]
Ang, M. [3 ]
Kanesvaran, R. [3 ]
Jain, A. [3 ]
Lim, T. K. H. [7 ]
Gogna, A. [8 ]
Koh, M. [9 ]
Yip, C. S. P. [10 ]
Thng, C. H. [2 ]
Chowbay, B. [11 ]
Tan, M. H. [3 ]
Lim, W. [3 ]
机构：
[1] Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore
[2] Natl Canc Ctr Singapore, Oncol Imaging, Singapore, Singapore
[3] Natl Canc Ctr, Med Oncol, Singapore, Singapore
[4] Natl Canc Ctr Singapore, Clin Trial Off, Singapore, Singapore
[5] Moh Holdings, Diagnost Radiol, Singapore, Singapore
[6] Moh Holdings, Singapore, Singapore
[7] Singhealth, Anat Pathol, Singapore, Singapore
[8] Singhealth, Diagnost Radiol, Singapore, Singapore
[9] Singhealth, Pulmonol, Singapore, Singapore
[10] Natl Canc Ctr Singapore, Radiat Oncol, Singapore, Singapore
[11] Natl Canc Ctr Singapore, Med Sci & Clin Pharmacol, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR T790M; osimertinib; NSCLC;
D O I：
10.1016/j.jtho.2017.09.1458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-017
引用
收藏
页码：S2206 / S2206
页数：1
相关论文
共 50 条
  • [1] High-dose aumolertinib versus osimertinib in EGFR T790M+NSCLC patients with brain metastases (ATTACK)
    Lu, S.
    Han, L.
    Lv, D.
    Zhang, Z.
    Wu, J.
    Wang, Q.
    Dong, X.
    Hu, Y.
    Chen, J.
    Wu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S86 - S86
  • [2] Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M
    Masuhiro, Kentaro
    Shiroyama, Takayuki
    Suzuki, Hidekazu
    Takata, So
    Nasu, Shingo
    Takada, Hiromune
    Morita, Satomu
    Tanaka, Ayako
    Morishita, Naoko
    Okamoto, Norio
    Hirashima, Tomonori
    ANTICANCER RESEARCH, 2018, 38 (06) : 3567 - 3571
  • [3] ACTIVITY AND TOLERABILITY OF COMBINED EGFR TARGETING WITH AFATINIB (BIBW 2992) AND CETUXIMAB IN T790M+NSCLC PATIENTS
    Horn, Leora
    Groen, Harry J. M.
    Smit, Egbert F.
    Janjigian, Yelena Y.
    Fu, Yali
    Wang, Fei
    Shahidi, Mehdi
    Denis, Louis
    Pao, William
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S361 - S362
  • [4] Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study
    Zhou, Bin
    Gong, Qiang
    Li, Ben
    Qie, Hai-Ling
    Li, Wei
    Jiang, Hong-Tao
    Li, He-Fei
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (05) : 643 - 651
  • [5] Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients
    Wang, S.
    Zhang, B.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S409 - S409
  • [6] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [7] Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients
    Meng, Hongxue
    Huang, Lan
    Wang, Jiahui
    Zhou, Yingxu
    Wang, Meng
    Yang, Zhaoyang
    Hong, Xuan
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (12)
  • [8] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
    Zhao, S.
    Jiang, T.
    Li, X.
    Zhao, C.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
  • [9] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
    Zhang, X.
    Wu, Y-L.
    Chen, Y.
    Zhang, H.
    Wu, G.
    Lu, Y.
    Liang, Z.
    Hu, Y.
    Cheng, Y.
    Wang, J.
    Ying, J.
    Liu, W.
    Liang, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
  • [10] ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC
    Wu, Y.
    Cho, B. C.
    Zhou, Q.
    Chang, G.
    Jiang, L.
    Metro, G.
    Martin, C.
    De Castro, G.
    Vansteenkiste, J.
    Vicente, D.
    Milner, A.
    Rigas, J.
    Chen, Y.
    Provencio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S358 - S359
12345